Validation of HAV biomarker 2A for differential diagnostic of hepatitis A infected and vaccinated individuals using multiplex serology.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractWorldwide about 1.5 million clinical cases of hepatitis A virus (HAV) infections occur every year and increasingly countries are introducing HAV vaccination into the childhood immunization schedule with a single dose instead of the originally licenced two dose regimen. Diagnosis of acute HAV infection is determined serologically by anti-HAV-IgM detection using ELISA. Additionally anti-HAV-IgG can become positive during the early phase of symptoms, but remains detectable after infection and also after vaccination against HAV. Currently no serological marker allows the differentiation of HAV vaccinated individuals and those with a past infection with HAV. Such differentiation would greatly improve evaluation of vaccination campaigns and risk assessment of HAV outbreaks. Here we tested the HAV non-structural protein 2A, important for the capsid assembly, as a biomarker for the differentiation of the immune status in previously infected and vaccinated individuals.
CitationValidation of HAV biomarker 2A for differential diagnostic of hepatitis A infected and vaccinated individuals using multiplex serology. 2017, 35 (43):5883-5889 Vaccine
AffiliationHelmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7, 38124 Braunschweig, Germany.
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-sa/4.0/
- Evaluation of an immunochromatographic assay for the detection of anti-hepatitis A virus IgM.
- Authors: Lee HJ, Jeong HS, Cho BK, Ji MJ, Kim JH, Lee AN, Lee KR, Cheon DS
- Issue date: 2010 Jul 19
- Diagnostic relevance of immunoglobulin G avidity for hepatitis A virus.
- Authors: Roque-Afonso AM, Grangeot-Keros L, Roquebert B, Desbois D, Poveda JD, Mackiewicz V, Dussaix E
- Issue date: 2004 Nov
- Response to comment on: Validation of HAV biomarker 2A for differential diagnostic of hepatitis A infected and vaccinated individuals using multiplex serology.
- Authors: Bohm K, Krause G, Sievers C
- Issue date: 2018 Jun 22
- Genotypes of hepatitis a virus in Turkey: first report and clinical profile of children infected with sub-genotypes IA and IIIA.
- Authors: Yilmaz H, Karakullukcu A, Turan N, Cizmecigil UY, Yilmaz A, Ozkul AA, Aydin O, Gunduz A, Mete M, Zeyrek FY, Kirazoglu TT, Richt JA, Kocazeybek B
- Issue date: 2017 Aug 11
- Early infection and asymptomatic spread of hepatitis A virus in a public child care center in Rio de Janeiro, Brazil: should attending children under two years of age be vaccinated?
- Authors: Morais LM, de Paula VS, Arantes MR, Oliveira ML, Gaspar AM
- Issue date: 2006 Jun